Results 191 to 200 of about 13,918 (210)
Some of the next articles are maybe not open access.

Acute toxicity and early PSA response after two-fraction stereotactic radiotherapy for localized prostate cancer using peri-rectal spacing - Initial report of the SABR-Dual trial.

International Journal of Radiation Oncology, Biology, Physics
PURPOSE SABR-Dual is a phase III trial with an initial phase-I safety cohort, of two-fraction stereotactic radiotherapy (SABR) with optional MRI-based focal boost, using peri-rectal spacing, for localized prostate cancer.
E. Fredman   +9 more
semanticscholar   +1 more source

Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).

Journal of Clinical Oncology
TPS489 Background: Optimal strategies for managing oligometastatic renal cell carcinoma (RCC) are unclear. While systemic therapy is the accepted standard, Stereotactic Ablative Radiation (SAbR) is a promising alternative based on retrospective and ...
R. Hannan   +15 more
semanticscholar   +1 more source

The Management of Stage I Non-Small Cell Lung Cancer (NSCLC) in Ontario: A Population-Based Study of Patterns of Care and Stereotactic Ablative Body Radiotherapy (SABR) Utilization from 2010-2019.

Radiotherapy and Oncology
BACKGROUND Stereotactic Ablative Body Radiotherapy (SABR) is the standard of care for medically inoperable patients with Stage I NSCLC. The adoption of SABR and its association with cancer outcomes requires characterization.
A. Ashworth   +4 more
semanticscholar   +1 more source

SABR for Metastasis-Directed Therapy — What We’ve Learned and What’s to Come

Nature Reviews Clinical Oncology, 2020
Tyler P Robin, Jeffrey R Olsen
exaly  

Trials of Locoregional Therapies Inspired by SABR-COMET

Lancet, The, 2020
Martijn R Meijerink   +2 more
exaly  

Points to Consider Regarding the SABR-COMET Trial

Lancet, The, 2020
Tom Treasure, Fergus Macbeth
exaly  

A Rough SABR Formula

Frontiers of Mathematical Finance, 2022
Jim Gatheral, Masaaki Fukasawa
exaly  

Points to Consider Regarding the SABR-COMET Trial – Authors' Reply

Lancet, The, 2020
David A Palma   +2 more
exaly  

Home - About - Disclaimer - Privacy